Last update 23 Mar 2025

QX-005N

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HDM3016, QX 005N, SNC005
+ [1]
Target
IL-4Rα
Action
inhibitors
Mechanism
IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors)
Therapeutic Areas
Immune System DiseasesInfectious DiseasesCongenital Disorders+ [3]
Active Indication
prurigo nodularisDermatitis, AtopicChronic rhinosinusitis with nasal polyps+ [3]
Inactive Indication-
Originator Organization
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
Active Organization
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (China)
Login to view timeline

Related

20
Clinical Trials associated with QX-005N
CTR20241178
/ RecruitingPhase 2
一项评价QX005N在中国中度至重度特应性皮炎青少年受试者中的安全性、药代动力学和有效性的临床研究
[Translation] A clinical study evaluating the safety, pharmacokinetics and efficacy of QX005N in Chinese adolescent subjects with moderate to severe atopic dermatitis
CTR20241660
/ RecruitingPhase 3
一项评价QX005N在治疗结节性痒疹成人受试者中的有效性和安全性的多中心、随机、双盲、安慰剂对照的III期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of QX005N in the treatment of adult subjects with nodular prurigo
ChiCTR2400082755
/ RecruitingPhase 1/2IIT
A clinical trial evaluating the safety, pharmacokinetics, and efficacy of QX005N in adolescent patients with moderate to severe atopic dermatitis in China - QX005NA-06
100 Clinical Results associated with QX-005N
Login to view more data
100 Translational Medicine associated with QX-005N
Login to view more data
100 Patents (Medical) associated with QX-005N
Login to view more data
100 Deals associated with QX-005N
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
prurigo nodularisPhase 3
China
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
22 May 2024
Dermatitis, AtopicPhase 3
China
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
28 Apr 2024
Chronic rhinosinusitis with nasal polypsPhase 2
China
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
03 Mar 2023
Pulmonary Disease, Chronic ObstructiveIND Approval
China
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
15 Sep 2023
AsthmaIND Approval
China
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
22 Feb 2022
Chronic UrticariaIND Approval
China
Qyuns Therapeutics Co., Ltd.Qyuns Therapeutics Co., Ltd.Startup
27 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free